Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Birth Defects Prevention Act of 1997

This article was originally published in The Tan Sheet

Executive Summary

Birth Defects Prevention Act of 1997: Substitute bill S 419 passes Senate by voice vote June 12 and is referred to the House Commerce Committee. The bill would "provide surveillance, research and services aimed at prevention of birth defects," including "public awareness strategies, such as programs using folic acid vitamin supplements to prevent spina bifida." S 419 calls for the Centers for Disease Control & Prevention to collect and analyze data on birth defects, operate regional research centers and provide public education. The bill allocates $30 mil. for fiscal 1998, $40 mil. for FY 1999 and "such sums as may be necessary" for FYs 2000 and 2001. A House bill identical to the original S 419, which gives CDC less discretion, also is before House Commerce...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel